GSK announced today that it welcomed the jury verdict in the Valadez case, in which the Illinois State Court ruled in favor of GSK in the first trial involving Zantac.

The court's decision reflects the scientific consensus that ranitidine does not increase the risk of cancer, supported by 16 epidemiological studies.

GSK assures that it will continue to defend itself against other claims, and notes that the court rejected the plaintiff's claim for 'punitive' damages.

In another case, the court also dismissed the next Zantac lawsuit (the Williams case), arguing that GSK was not the manufacturer of the OTC product at the time of its alleged use by the plaintiff, and therefore not liable for the consequences.

Copyright (c) 2024 All rights reserved.